MK3207 for Treatment of Acute Migraines (3207-005)

Phase 2 Completed 676 enrolled Merck Sharp & Dohme LLC

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to demonstrate the effectiveness and appropriate dosage level of MK3207 in the treatment of acute migraine.

Timeline

Start: 2008-07
Primary completion: 2009-01
Completion: 2009-01

Outcome

Met primary endpoint

paper A positive dose-response trend was demonstrated when data were combined across all MK-3207 doses for two-hour pain freedom (p < .001). PMID 21383045 ↗

Publications

Results Hewitt DJ, Aurora SK, Dodick DW, Goadsby PJ, Ge YJ, Bachman R, Taraborelli D, Fan X, Assaid C, Lines C, Ho TW. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011 Apr;31(6):712-22. doi: 10.1177/0333102411398399. Epub 2011 Mar 7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MK3207	Small molecule	2.5 mg	—
Subject	MK3207	Small molecule	5 mg	—
Subject	MK3207	Small molecule	10 mg	—
Subject	MK3207	Small molecule	20 mg	—
Subject	MK3207	Small molecule	50 mg	—
Subject	MK3207	Small molecule	100 mg	—
Subject	MK3207	Small molecule	200 mg	—